Variant Ciz1 is a circulating biomarker for early-stage lung cancer

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 109; no. 45; pp. E3128 - E3135
• Main Authors: Higgins, Gillian, Roper, Katherine M, Watson, Irene J, Blackhall, Fiona H, Rom, William N, Pass, Harvey I, Ainscough, Justin F. X, Coverley, Dawn
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 06.11.2012; National Acad Sciences
• Series: PNAS Plus
• Subjects: Adult; Aged; Alternative Splicing - genetics; Animals; Biological Sciences; biomarkers; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Cell Line, Tumor; Cell Proliferation; Cells; Deoxyribonucleic acid; DNA; DNA replication; Female; Gene Expression Regulation, Neoplastic; Humans; Lung cancer; lung neoplasms; Lung Neoplasms - blood; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Mice; Middle Aged; neoplasm cells; Neoplasm Staging; NIH 3T3 Cells; Nuclear Proteins - blood; Nuclear Proteins - genetics; patients; Plasma; PNAS Plus; Proteins; Sensitivity and Specificity; Tumors; Western blotting

There is an unmet need for circulating biomarkers that can detect early-stage lung cancer. Here we show that a variant form of the nuclear matrix-associated DNA replication factor Ciz1 is present in 34/35 lung tumors but not in adjacent tissue, giving rise to stable protein quantifiable by Western b...